Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
The primary objective will be to assess the overall response rate and to evaluate the
efficacy and safety of idelalisib (IDELA; GS-1101) in participants with previously treated
indolent Non-Hodgkin Lymphoma (iNHL) that is refractory both to rituximab and to
alkylating-agent-containing chemotherapy.
Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg
taken twice per day. Treatment with idelalisib can continue in compliant participants as long
as the study is still ongoing and the participants appear to be benefiting from treatment
with acceptable safety.